natgillin/translations-raw huggingface dataset:
Objective responses to nivolumab (according to the definition of the co-primary endpoint) were observed in patients with or without BRAF mutation-positive melanoma.
Objektivni odziv na nivolumab (glede na opredelitev sočasnega primarnega opazovanega dogodka) so opazili tako pri bolnikih z melanomom z mutacijo BRAF kot brez nje.
Objective responses to nivolumab were observed regardless of whether patients had tumours that were designated PD-L1 negative or PD-L1 positive (tumour membrane expression cut off of 5% or 10%).
Objektivni odziv na nivolumab so opazili ne glede na PD-L1 negativno ali PD-L1 pozitivno označenost tumorja (mejna vrednost ekspresije tumorske membrane 5 % ali 10 %).
Objective signs of inflammation population (OSI)
Populacija z objektivnimi znaki vnetja (OSI)
Objective testing was required for a retroperitoneal bleed (ultrasound or Computer Tomography (CT) scan) and for an intracranial and intraspinal bleed (CT scan or Magnetic Resonance Imaging).
Objektivna preiskava je bila potrebna zaradi retroperitonealne krvavitve (ultrazvočna preiskava ali računalniška tomografija) ter intrakranialne in intraspinalne krvavitve (računalniška tomografija ali magnetna resonanca).
Objective tumour responses / duration of response / progression
Objektivni tumorski odzivi / trajanje odziva / progresija
Objective, durable clinical responses were observed [67% ORR (95% CI: 48-85%), 11.8 months median DR (range: 4-17 months)] and resulted in a greater incidence of haematologic toxicity (see 4.8) than in Studies 1 and 2.
1. in 2. študijo so bili doseženi objektivni dolgotrajni klinični odgovori [67 % ORR (95 % CI: 48 – 85 %), 11,8 mesecev srednji DR (razpon: 4 – 17 mesecev)], ki so imeli za posledico višjo incidenco hematološke toksičnosti (glejte poglavje 4.8).
Obligation to complete post-authorisation measures
Obveznost izvedbe ukrepov po pridobitvi dovoljenja za promet
Obligation to complete post-authorisation measures
Obveznosti izvedbe ukrepov po pridobitvi dovoljenja za promet
Obligation to conduct post-authorisation measure
Obveznost izvedbe ukrepov po pridobitvi dovoljenja za promet z zdravilom
Obligation to conduct post-authorisation measures
Obveznost izvedbe ukrepov po pridobitvi dovoljenja
Obligation to conduct post-authorisation measures
Obveznosti izvajanja ukrepov po pridobitvi dovoljenja za promet
Obligation to conduct post-authorisation measures
Obveznosti izvedbe ukrepov po pridobitvi dovoljenja za promet
OBLIGATION TO CONDUCT POST-AUTHORISATION MEASURES
SPECIFIČNE ZAHTEVE ZA IZPOLNITEV UKREPOV PO PRIDOBITVI DOVOLJENJA ZA PROMET Z ZDRAVILOM
Obligation to conduct post-authorisation measures:
Obveznost izvedbe ukrepov po pridobitvi dovoljenja za promet:
Obligation to conduct post‐authorisation measures
Obveznost izvedbe ukrepov po pridobitvi dovoljenja za promet
Obligations of health care professionals in relation to the prescribing of Volibris:
Obveznosti zdravstvenih delavcev v zvezi s predpisovanjem zdravila Volibris:
Obligations of the health care professional in relation to the prescribing of pomalidomide
obveznosti, ki jih morajo zdravstveni delavci upoštevati pri predpisovanju pomalidomida:
Obligations to conduct post-authorisation measures
Obveznost izvedbe ukrepov po pridobitvi dovoljenja za promet
obliterans,
bolezen pljuč,
Oblong, opaque, blue and white capsule.
Podolgovate, neprozorne, modro-bele kapsule.
Oblong, opaque, green and white capsule.
Podolgovate, neprozorne, zeleno-bele kapsule.
Oblong, opaque, off-white to cream coloured, printed with ‘GX CC1’.
Podolgovate, neprozorne, sivobele do krem barve, z oznako ‘GX CC1’.
Oblong, opaque, off-white to cream coloured, printed with ‘GX CC2’.
Podolgovate, neprozorne, sivobele do krem barve, z oznako ‘GX CC2’.
Observation for infusion reactions is recommended during and for 2 hours after LEMTRADA infusion.
Priporočljivo je opazovanje bolnikov glede z infuzijo povezanih reakcij med infundiranjem zdravila LEMTRADA in še 2 uri po njem.
Observation N= 1697***
n = 1697
Observation N=1693
n = 1693
observational registry study shall evaluate the outcomes of pregnancy in women
Prospektivna, opazovalna registrska študija bo ocenjevala izide
observational safety study.
da bo izvedel primerjalno opazovalno študijo dolgoročne varnosti.
Observational studies of long-term effectiveness of varicella vaccine
Opazovalne študije dolgotrajne učinkovitosti cepiva proti noricam
Observe the patient for 30 minutes to ensure that you will notice if the patient develops an allergic or hypersensitivity reaction (immediate type).
Bolnika opazujte 30 minut in bodite pozorni, če se pri bolniku razvije alergijska ali preobčutljivostna reakcija (takojšnjega tipa).
Observe the patient frequently and carefully for the entire duration of the infusion and for at least 15 minutes after completion of the infusion for:
Pri bolniku je treba med infundiranjem in še vsaj 15 minut po zaključku infundiranja pogosto in skrbno preveriti, če ima:
Observe the vial for any undissolved powder.
Poglejte, ali je v viali še kaj neraztopljenega praška.
Observed benefits on lung function and P. aeruginosa suppression should be assessed in the context of the patient’s tolerance of TOBI Podhaler.
Koristnost zdravljenja z izboljšanjem pljučne funkcij in zmanjšanjem števila bakterij P. aeruginosa je treba presojati skupno s prenašanjem zdravila TOBI Podhaler.
Observed changes in the laboratory parameters are: increased WBC count, basophils, eosinophils, monocytes and neutrophils, AST, ALT, LDH, total bilirubin and total protein; lowered RBC count and total protein.
Opažene spremembe laboratorijskih parametrov so: povečano število belih krvnih celic, bazofilcev, eozinofilcev, monocitov in nevtrofilcev, AST, ALT, LDH, celotni bilirubin in celotne beljakovine; znižano število rdečih krvnih celic in celotnih beljakovin.
Observed data
Opaženi podatki
Observed data
Ugotovljeni podatki
Observed data
Zabeleženi
Observed difference (95% CI) ±
opažena razlika (95% IZ) ±
Observed difference vs placebo
Opažena razlika v prim. s placebom
observed during prolonged co-
lahko opazi med podaljšano
observed during prolonged co-
lamotrigina.
Observed elevations of ALT and/or AST
Opaženo povečanje vrednosti ALT in/ali AST
observed following coadministration
dajanjem zdravil
Observed in at least 2 subjects of the same subtype.
Opažene pri vsaj 2 preiskovancih iste podvrste.
Observed in at least 2 subjects of the same subtype.
Opažene pri vsaj 2 preiskovancih istega podtipa.
Observed in combination in 6% (4/67) of the subjects.
Opaženo v kombinaciji pri 6 % (4/67) preiskovancev.
Observed in combination in genotype 1b-infected subjects.
Opaženo v kombinaciji pri preiskovancih, okuženih z genotipom 1b.
Observed in patients taking concomitant glucocorticosteroids.
# pri bolnikih, ki so sočasno jemali glukokortikoide.
Observed in patients with Parkinson’s disease
Opaženo pri bolnikih s Parkinsonovo boleznijo
Observed in patients with Restless Legs Syndrome
Opaženo pri bolnikih z RLS
observed in some patients during ribavirin combination therapy with peginterferon alfa-2b or interferon alfa-2b, and even after treatment discontinuation mainly during the 6-month follow-up period.
Pri nekaterih bolnikih so med kombinirano terapijo z ribavirinom in peginterferonom alfa-2b ali interferonom alfa-2b opažali hude učinke na CŽS, še posebej depresijo, samomorilne misli in tudi poskus samomora, celo po ukinitvi zdravljenja, predvsem v 6-mesečnem obdobju spremljanja.
observed in tipranavir PK
očasni uporabi majhnih odmerkov
observed induction.
Metadon
observed pharmacokinetic
opažene farmakokinetične
Observed post-marketing with paliperidone
Neželeni učinki, o katerih so poročali v obdobju trženja pri zdravljenju s paliperidonom.
Observed treatment difference vs placebo (%)
Opažena terapevtska razlika v prim. s placebom (%)
Observed treatment difference vs placebo (mean difference)
Opažena terapevtska razlika v prim. s placebom (povprečna razlika)
observed with other ritonavir-boosted protease
jetrnih neželenih učinkov.
observed.
opazili.
Observed:
Opazovano:
obsessive behaviour(s)
obsesivno vedenje;
Obsessive thoughts or impulsive behaviour.
obsesivne misli in impulzivno vedenje,
Obsessive thoughts or impulsive behaviour.
Obsesivne misli in impulzivno vedenje.
Obsessive-
obsesivno
Obsessive- compulsive disorder, agitationd
obsesivno kompulzivna motnja, agitiranostd
Obstruction in the gut, inflammation of the large bowel, inflammation of the bile duct
zapora črevesa, vnetje debelega črevesa, vnetje žolčevoda
obstruction of the bowel
obstrukcija črevesja
obstruction of the gut, increased blood level of the enzyme amylase, reflux of stomach contents in your throat, delayed emptying of the stomach
zapora pretoka črevesne vsebine, zvišane vrednosti encima amilaze v krvi, refluks želodčne vsebine v žrelo, zakasnitev praznjenja želodca
obstruction, Ascites,
obstrukcija, ascites,
Obstructive airways disorder
obstruktivna motnja dihalnih poti
Obstructive uropathy Haematuria
obstruktivna uropatija hematurija
OBT
(N = 237)
OBT
126 (107,
Obtain 900  200 MBq of freshly eluted 99mTc sodium pertechnetate eluate from any commercial source which has been eluted within the past 24 hours.
Vzemite 900  200 MBq sveže izpranega 99mTc eluata natrijevega pertehnetata iz kateregakoli komercialno dostopnega vira, ki je bil izpran v zadnjih 24 urah.
obtained with a reduced
podatkov pri zmanjšanem
Obvious signs of bleeding
očitne znake krvavitve
Occasional allergic reactions have been associated with mifamurtide treatment, including rash, shortness of breath and Grade 4 hypertension (see section 4.8).
Zdravljenje z mifamurtidom je bilo občasno povezano s pojavom alergijskih reakcij, vključno z izpuščajem, zasoplostjo in hipertenzijo 4. stopnje (glejte poglavje 4.8).
Occasional side effects of Melosus are those seen with NSAIDs, such as loss of appetite, vomiting, diarrhoea, blood appearing in the stools, renal failure and apathy (lack of vitality).
Občasni neželeni učinki zdravila Melosus so enaki kot pri drugih nesteroidnih protivnetnih zdravilih in obsegajo izgubo teka, bruhanje, drisko, kri v blatu, odpoved ledvic in apatijo (pomanjkanje vitalnosti).
occasionally
občasno povezane s
Occasionally a slight increase of the temperature (0.5 ºC – 1.0 ºC) is observed for 24–48 hours after the administration of a double dose of the vaccine.
Občasno je mogoče opaziti blago povišanje telesne temperature (0,5 ºC–1,0 ºC), ki traja 24–48 ur po dajanju dvojnega odmerka cepiva.
Occasionally a young person who is taking this medicine may be reading the package leaflet, but usually it will be a parent/carer.
Občasno se zgodi, da mlada oseba, ki jemlje to zdravilo, sama prebere navodilo za uporabo, vendar pa ga običajno preberejo starši ali skrbnik.
Occasionally abscess formation occurred.
Občasno se je pojavil absces.
occasionally associated
občasno povezane s
occasionally associated with
občasno povezane s ketoacidozo ali
occasionally associated with
sladkorne bolezni, občasno povezane s
Occasionally debridement and, less often, skin grafting are required and healing may take up to 6 months.
Za zdravljenje je včasih potrebno čiščenje in redkeje presaditev kože, zdravljenje pa lahko traja do 6 mesecev.
Occasionally hardened minor local swellings (0.5 – 2.0 cm) were observed which disappeared within 21 days after vaccination.
Občasno so zasledili manjše otekline v obliki zatrdlin (0,5 do 2,0 cm), ki so minile v 21 dneh po cepljenju.
Occasionally, cats will develop temporary apathy (loss of interest in surroundings) and anorexia (loss of appetite), as well as hyperthermia (elevated body temperature) lasting for one or two days.
Občasno se lahko pri mačkah pojavi začasna apatija (pomanjkanje zanimanja za okolico) in anoreksija (izguba teka) ter hipertermija (povišana telesna temperatura), ki traja dan ali dva.
Occasionally, cats will develop temporary apathy (loss of interest in surroundings) and anorexia (loss of appetite), as well as hyperthermia (elevated body temperature) lasting for one or two days.
Občasno se lahko pri mački pojavi začasna apatija (izguba interesa za okolico) in anoreksija (izguba apetita) ter hipertermija (zvišana telesna temperatura), ki traja en dan ali dva.
Occasionally, cats will develop temporary apathy (loss of interest in surroundings) and anorexia (loss of appetite), as well as hyperthermia (elevated body temperature) lasting for one or two days.
Občasno se lahko pri mački pojavi začasna apatija (pomanjkanje zanimanja za okolico) in anoreksija (izguba teka) ter hipertermija (povišana telesna temperatura), ki traja dan ali dva.
Occasionally, during INTELENCE treatment, you can experience hypersensitivity reaction (allergic reaction including rash and fever but also swelling of the face, tongue or throat, difficulty in breathing or swallowing) which could be potentially life-threatening.
Med zdravljenjem z zdravilom INTELENCE se občasno lahko pojavi preobčutljivostna reakcija (alergijska reakcija, vključno z izpuščajem in povišano telesno temperaturo in tudi z otekanjem obraza, jezika ali žrela, težavami z dihanjem ali požiranjem), ki je lahko življenjsko nevarna.
Occasionally, these symptoms can be a sign of bowel inflammation (colitis)
Občasno so lahko ti simptomi znak vnetja črevesja (kolitisa).
Occlusion in the connection between artery and vein (shunt thrombosis) may occur especially if you have low blood pressure or if your arteriovenous fistula has complications.
Možna je obstrukcija spoja med arterijo in veno (tromboza šanta), še posebej, če imate nizek krvni tlak ali se na vaši arteriovenski fistuli kažejo zapleti.
occlusion of a blood vessel (embolism)
okluzija krvne žile (embolija)
occlusion of the vein at the back of the eye discharge of inner jelly of the eye
zapora vene v zadnjem delu očesa zdrs očesne steklovine
occlusive liver disease, hepatitic artery thrombosis
jeter, tromboza jetrne arterije
Occult blood loss
okultno izgubljanje krvi
Occult blood positive
pozitiven izid pri preverjanju prisotnosti prikrite krvi
occur due to mild inhibition of OATP1B1 by
Zaradi šibkega zaviranja OATP1B1 s
Occurred at various times up to several months after completion of MabThera therapy
Pojavili so se različno, tudi do nekaj mesecev po končanem zdravljenju z zdravilom MabThera.
Occurrence
Pojav
Occurrence
Pojavljanje
Occurrence
Pojavnost
Occurrence at 30 mg:
Pojavitev pri 30 mg:
Occurrence at 45 mg:
Pojavitev pri 45 mg:
Occurrence of certain side effects
Pojavnost določenih neželenih učinkov
Occurrence of skin symptom(s):
Pojav kožnih simptomov:
Occurrences of enterocolitis, including neutropaenic colitis, caecitis, and C. difficile colitis have been reported during treatment with clofarabine.
Med zdravljenjem s klofarabinom so opazili pojav enterokolitisa, vključno z nevtropeničnim kolitisom, tiflitisom in kolitisom zaradi C. difficile.
Occurrences of enterocolitis, including neutropaenic colitis, caecitis, and C. difficile colitis, have been reported during treatment with clofarabine.
Med zdravljenjem s klofarabinom so poročali o pojavih enterokolitisa, vključno z nevtropeničnim kolitisom, tifilitisom in kolitisom zaradi C. difficile.
Occurrences of lactic acidosis (in the absence of hypoxaemia) sometimes fatal, and usually associated with severe hepatomegaly with steatosis have been reported with the use of nucleoside/nucleotide analogues.
Poročali so, da je ob uporabi nukleozidnih/nukleotidnih analogov prišlo do pojava laktacidoz (brez hipoksemije), včasih s smrtnim izidom, običajno pa v povezavi s hudo hepatomegalijo in steatozo.
Occurrences of lactic acidosis (in the absence of hypoxaemia), sometimes fatal, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues.
Med uporabo nukleozidnih analogov je opisana laktacidoza (v odsotnosti hipoksemije), ki je bila v nekaterih primerih smrtna in je bila ponavadi povezana s hudo hepatomegalijo in steatozo jeter.
occurs, then continue with therapy
nato se nadaljuje z zdravljenjem
Oceanside, CA 92056 5802 USA
Oceanside, CA 92056 5802 ZDA
Oceanside, CA 92056 USA
Oceanside, CA 92056 ZDA
Oclacitinib
oklacitinib
Oclacitinib is metabolised in the dog to multiple metabolites.
Oklacitinib se presnovi v številne presnovke.
Oclacitinib modulates the immune system and may increase susceptibility to infection and exacerbate neoplastic conditions.
Oklacitinib modulira imunski sitem in lahko poveča dovzetnost za okužbe ter poslabša neoplastične bolezni.
Oclacitinib tablets were administered to healthy, one year old Beagle dogs twice daily for 6 weeks, followed by once per day for 20 weeks, at 0.6 mg/kg bw, 1.8 mg/kg bw and 3.0 mg/kg bw for a total of 26 weeks.
Tablete oklacitiniba so v odmerku 0,6 mg/kg telesne mase, 1,8 mg/kg in 3 mg/kg v skupnem trajanju 26 tednov dajali zdravim enoletnim psom pasme beagle, 6 tednov dvakrat dnevno, nato 20 tednov enkrat dnevno.
OCT retinal thickness at center subfield mean average change over 3 years, AUC approach (µm)
Srednja povprečna sprememba debeline centralnega podpolja očesne mrežnice, izmerjena z OKT, v 3 letih, pristop AUC (µm)
OCT1 at clinically relevant concentrations.
OATP1B3, OAT1 in OCT1.
OCT2 substrates
Substrati za OCT2
October 23rd, 2000
23. oktober 2000
October 26,
26. oktober 2011
Octocog alfa (recombinant human coagulation factor VIII)
oktokog alfa (rekombinantni humani koagulacijski faktor VIII)
Octreotide
oktreotid
Octreotide and lanreotide (used for treatment of acromegaly, a rare hormonal disorder that usually occurs in middle–aged adults, caused by the pituitary gland producing excess growth hormone) may either increase or decrease your blood sugar level.
Oktreotid in lanreotid (uporabljata se za zdravljenje akromegalije, redke hormonske motnje, ki se ponavadi pojavi pri odraslih osebah srednjih let in je posledica čezmernega nastajanja rastnega hormona v žlezi hipofizi) lahko zvišata ali znižata vaš krvni sladkor.
Octreotide/lanreotide may both decrease and increase insulin requirement.
Oktreotid/lanreotid lahko potrebo po insulinu zmanjša ali zveca.
Octyl salicylate Isopropyl alcohol
Oktilsalicilat Izopropilalkohol
Ocular
očesna
Ocular
Očesni
Ocular
vid
Ocular adverse events
Očesni neželeni učinki
Ocular adverse events (see section 4.8) including retinal haemorrhages, cotton wool spots, and retinal artery or vein obstruction have been reported in rare instance after treatment with alpha interferons.
V redkih primerih so po zdravljenju z alfa interferoni poročali o očesnih neželenih dogodkih (glejte poglavje 4.8), npr. krvavitvah v mrežnico, bombažu podobnih lisah in zamašitvi mrežnične arterije ali vene.
Ocular burning
pekoč občutek v očesu,
Ocular changes were inconsistently observed in repeat dose toxicity studies in rodents and dogs, butnot in monkeys.
V študijah toksičnosti pri ponavljajočih odmerkih so pri glodalcih in psih, ne pa tudi pri opicah, občasno opazili spremembe na očeh.
Ocular corneal infiltrates:
Očesni roženični infiltrati
Ocular disorders
Očesne bolezni
Ocular events
Očesni neželeni učinki
ocular hyperaemia
hiperemija očesa
Ocular hyperaemia
hiperemija veznice, očesna hiperemija
Ocular hyperaemia
okularna hiperemija
Ocular hyperaemia
očesna hiperemija
Ocular hyperaemia Conjunctivitis, eye pain Uveitis, episcleritis, iritis
konjunktivitis, bolečina v očesu
ocular hyperaemia, iris hyperpigmentation
očesna hiperemija, hiperpigmentacija šarenice
ocular hypertension
očesni hipertenziji
Ocular hypertension, cataract subcapsular, vitreous haemorrhage*, visual acuity reduced*, visual impairment/ disturbance, vitreous detachment*, vitreous floaters*, vitreous opacities*, blepharitis, eye pain*, photopsia*, conjunctival oedema* conjunctival hyperaemia*
Očesna hipertenzija, subkapsularna katarakta, vitrealna krvavitev*, zmanjšana ostrina vida*, okvara vida/motnje vida, odstop steklovine*, plavajoče motnjave v steklovini*, motnjave v steklovini*, blefaritis, bolečine v očesu*, fotopsija*, edem očesne veznice*, hiperemija veznice
Ocular hypertension, cataract subcapsular, vitreous haemorrhage*, visual acuity reduced*, visual impairment/ disturbance, vitreous detachment*, vitreous floaters*, vitreous opacities*, blepharitis, eye pain*, photopsia*, conjunctival oedema* conjunctival hyperaemia*
Očesna hipertenzija, subkapsularna katarakta, vitrealna krvavitev*, zmanjšana ostrina vida*, slabovidnost/motnje vida, odstop steklovine*, plavajoče motnjave v steklovini*, motnjave v steklovini*, blefaritis, bolečine v očesu*, fotopsija*, edem očesne veznice*, hiperemija veznice
ocular icterus
očesni ikterus
ocular icterus (presence of jaundice in the white part of the eyes, i.e. the eyes become yellow)
očesni ikterus (zlatenica, ki se kaže kot rumeno obarvanje očesnih beločnic (oči postanejo
ocular icterus, vision blurred, eyelid oedema, lacrimation increased
očesni ikterus, zamegljen vid, edem očesne veke, povečano solzenje
Ocular infection
Okužba očesa
Ocular inflamma tion†**
vnetje oči
Ocular inflammat ion†**
vnetje oči
Ocular inflammati on†**
vnetje oči
Ocular inflammation
Vnetje oči
Ocular inflammation events such as uveitis, episcleritis and scleritis have been reported with ibandronic acid.
Pri zdravljenju z ibandronsko kislino, so poročali o vnetnih stanjih oči, kot so uveitis, episkleritis in skleritis.
Ocular inflammation*†
očesno vnetje
Ocular inflammation*†
vnetje oči
Ocular inflammation†
očesno vnetje
Ocular inflammation†**
vnetje oči
ocular pruritus, growth of eyelashes
očesni pruritus, rast trepalnic
Ocular use
Pot uporabe
Ocular use
uporaba
Ocular use
Za okularno uporabo.
Ocular use.
za okularno uporabo
Ocular use.
Za okularno uporabo.
Ocular/intranasal administration or coarse spray gives the best responses and these should be the methods of choice, especially when vaccinating young chickens.
Po okularnem ali intranazalnem dajanju ter razprševanju z večjimi kapljicami je odzivnost najboljša, zato so ti načini izbirni načini dajanja, zlasti pri cepljenju mladih piščancev.
oculogyration) 11
okulogiracijo)11
oculogyration)11
diskinezije
oculogyration)11
okulogiracijo)11
oculogyration)11
z okulogiracijo)11
Oculogyric crises, activation of latent Horner's syndrome, blepharospasm
okulogirna kriza, aktivacija latentnega Hornerjevega sindroma, blefarospazem
Oculogyric crisis Vision blurred Eye pain Diplopia
okulogirna kriza zamegljen vid bolečina v očeh diplopija
Oculonasal administration:
Okulonazalno dajanje:
Oculonasal or in drinking water use.
Okulonazalno dajanje ali dajanje v vodi za pitje
Oculonasal use
Okulonazalna uporaba
Odd ratio
Razmerje obetov
Odds ratio
Razmerje obetov
Odds ratio (95% CI)
(95-% IZ)
Odds Ratio (95% CI)
Razmerje verjetnosti
Odds Ratio (95% CI)
Razmerje verjetnosti (95-odstotni IZ)
Odds ratio (95% CI) vs placebo
Razmerje obetov (95 % IZ) v prim. s placebom
Odds Ratio (95% CI) vs.
Razmerje obetov (95 % IZ) v primerjavi z MTX
Odds ratio (95% CI)+
Razmerje obetov (95-odstotni IZ)+
Odds ratio (CHAMPIX vs.
razmerje obetov
Odds ratio (lipegfilgrastim / placebo), CI and p-value out of multivariate logistic regression analysis
Razmerje obetov (lipegfilgrastim/placebo), IZ in vrednost p iz multivariantne logistične regresijske analize
Odds Ratio (OR) (95%CI)
Razmerje obetov (95-%IZ)
Odds ratio 1.56;
Razmerje obetov 1,56;
Odds Ratio 2.77
razmerje obetov 2,77
Odds Ratio 3.02
razmerje obetov 3,02
Odds Ratio 3.45
razmerje obetov 3,45
Odds ratio, increase in the likelihood of achieving the MCID compared to placebo.
c Razmerje verjetnosti, povečanje verjetnosti za MCID v primerjavi s placebom.
Odds Ratio: 1.36 [0.78; 2.37]
Razmerje obetov: 1,36 [0,78; 2,37]
Odds ratio: 4.49 (2.96, 6.83)
Razmerje obetov: 4,49 (2,96, 6,83)
Odds ratio: 4.76 (3.24, 7.00)
Razmerje obetov: 4,76 (3,24, 7,00)
Odefsey 200 mg/25 mg/25 mg film-coated tablets
Odefsey 200 mg/25 mg/25 mg filmsko obložene tablete
Odefsey 200 mg/25 mg/25 mg film-coated tablets emtricitabine/rilpivirine/tenofovir alafenamide
Odefsey 200 mg/25 mg/25 mg filmsko obložene tablete emtricitabin/rilpivirin/alafenamidtenofovirat
Odefsey [Outer packaging only]
Odefsey [samo na zunanji ovojnini]
Odefsey comes in bottles of 30 tablets and in packs made up of 3 bottles, each containing 30 tablets.
Zdravilo Odefsey je na voljo v HDPE vsebnikih po 30 tablet in v pakiranjih s po 3 HDPE vsebniki, od katerih vsak vsebuje 30 tablet.